全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia

DOI: 10.1186/1476-4598-9-123

Full-Text   Cite this paper   Add to My Lib

Abstract:

By comparing the expression profiles of these two groups of patients, we identified a microRNA signature able to distinguish refractory from sensitive CLLs. The expression of some microRNAs was also able to predict fludarabine resistance of 12 independent CLL patients. Among the identified microRNAs, miR-148a, miR-222 and miR-21 exhibited a significantly higher expression in non-responder patients either before and after fludarabine treatment. After performing messenger RNA expression profile of the same patients, the activation of p53-responsive genes was detected in fludarabine responsive cases only, therefore suggesting a possible mechanism linked to microRNA deregulation in non-responder patients. Importantly, inhibition of miR-21 and miR-222 by anti-miRNA oligonucleotides induced a significant increase in caspase activity in fludarabine-treated p53-mutant MEG-01 cells, suggesting that miR-21 and miR-222 up-regulation may be involved in the establishment of fludarabine resistance.This is the first report that reveals the existence of a microRNA profile that differentiate refractory and sensitive CLLs, either before and after fludarabine mono-therapy. A p53 dysfunctional pathway emerged in refractory CLLs and could contribute in explaining the observed miRNA profile. Moreover, this work indicates that specific microRNAs can be used to predict fludarabine resistance and may potentially be used as therapeutic targets, therefore establishing an important starting point for future studies.Chronic Lymphocytic Leukemia (CLL) is the most common hematologic neoplasia in the Western world and is characterized by a clonal expansion of CD5+ B-cells. The disease may have a long and indolent course, not requiring treatment for years, or it may rapidly progress. Initially most patients respond to purine nucleoside analogs, which today represent pivotal agents for first and second-line treatment [1]. However a significant fraction of patients do not respond or become resistant

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133